IMR Press / FBL / Special Issues / 1460050983177834497

Protein Kinases and Phosphatases in Cancer

Submission deadline: 15 August 2022
Special Issue Editors
  • Georgios Giamas
    School of Life Sciences, University of Sussex, Brighton, UK
    Interests: Signaling; Cancer; Breast cancer; Glioblastoma; Microenvironment; Exosomes; Kinases
    Special Issues in IMR Press journals
  • Zahid Pranjol
    School of Life Sciences, University of Sussex, Brighton, UK
    Interests: Tumour microenvironment and regulation of cell signalling in response to tumour secreted factors
Special Issue Information

Dear Colleagues,

Protein kinases and phosphatases are integral parts of the cell signaling pathways and many are associated with cancer initiation and progression. Post-translational modification, mutation or other genetic alterations of oncogenic phosphatases or kinases can result in dysregulation of cell signaling pathways and subsequently lead to malignant transformation. Moreover, beyond their direct action on cancer cells, more indirect actions of kinases and phosphatases in the tumor microenvironment have also been shown to result in cancer regression. There are now many examples of such molecules being used as prognostic markers and potential therapeutic targets for various cancer types. Thus, it is not surprising to see the constant evolution and development of novel small molecule kinase/phosphatase drugs for preclinical and clinical uses. The Special Issue aims to present the latest findings in this field and will cover all topics relevant to kinases and phosphatases in human cancers. We invite researchers to contribute original research or review articles that focus on any aspect involving the role and function of kinases and phosphatases and their therapeutic developments in relation to cancer onset and progression.

Prof. Dr. Georgios Giamas and Dr. Zahid Pranjol

Guest editors

Oncogenic phosphatase
Oncogenic kinases
Tumour microenvironment
Cancer progression
Cell signaling in cancer development
Small-molecule inhibitors
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Back to top